STRYKER CORP (SYK) Quick Ratio
- Quick ratio · latest quarter: Value 1.08×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.08× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $7.22B ÷ $6.68B ≈ 1.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 7.22B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 6.68B USD | Liabilities, Current |
| Cash and equivalents | 3.39B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 85.00M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 3.74B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 5.52B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.22B | $6.68B | $3.39B | $85.00M | $3.74B | $5.52B | 1.08× |
| 2026-03-31 | $6.54B | $6.32B | $2.88B | $87.00M | $3.57B | $5.42B | 1.03× |
| 2025-12-31 | $8.14B | $7.79B | $4.01B | $89.00M | $4.04B | $5.31B | 1.04× |
| 2025-09-30 | $6.99B | $7.41B | $3.26B | $87.00M | $3.64B | $5.37B | 0.94× |
| 2025-06-30 | $6.38B | $7.29B | $2.38B | $89.00M | $3.92B | $5.29B | 0.88× |
| 2025-03-31 | $6.37B | $7.93B | $2.32B | $89.00M | $3.96B | $5.11B | 0.80× |
| 2024-12-31 | $7.73B | $7.62B | $3.65B | $91.00M | $3.99B | $4.77B | 1.01× |
| 2024-09-30 | $7.67B | $7.67B | $3.85B | $84.00M | $3.74B | $5.29B | 1.00× |
| 2024-06-30 | $5.58B | $6.93B | $1.87B | $83.00M | $3.62B | $5.04B | 0.81× |
| 2024-03-31 | $5.88B | $6.96B | $2.33B | $77.00M | $3.47B | $5.03B | 0.85× |
| 2023-12-31 | $6.82B | $7.92B | $2.97B | $82.00M | $3.77B | $4.84B | 0.86× |
| 2023-09-30 | $5.21B | $7.46B | $1.86B | $76.00M | $3.28B | $4.88B | 0.70× |
| 2023-06-30 | $4.74B | $6.58B | $1.40B | $77.00M | $3.26B | $4.59B | 0.72× |
| 2023-03-31 | $4.97B | $5.87B | $1.67B | $86.00M | $3.21B | $4.33B | 0.85× |
| 2022-12-31 | $5.49B | $6.30B | $1.84B | $84.00M | $3.56B | $4.00B | 0.87× |
| 2022-09-30 | $4.60B | $4.57B | $1.42B | $77.00M | $3.10B | $3.88B | 1.01× |
| 2022-06-30 | $4.27B | $4.40B | $1.04B | $83.00M | $3.15B | $3.75B | 0.97× |
| 2022-03-31 | $4.52B | $4.41B | $1.46B | $72.00M | $2.99B | $3.52B | 1.03× |
| 2021-12-31 | $6.04B | $4.55B | $2.94B | $75.00M | $3.02B | $3.31B | 1.33× |
| 2021-09-30 | $5.46B | $4.45B | $2.56B | $76.00M | $2.82B | $3.43B | 1.23× |
| 2021-06-30 | $5.04B | $4.25B | $2.24B | $84.00M | $2.71B | $3.43B | 1.19× |
| 2021-03-31 | $4.93B | $3.95B | $2.24B | $74.00M | $2.62B | $3.47B | 1.25× |
| 2020-12-31 | $5.72B | $5.04B | $2.94B | $81.00M | $2.70B | $3.49B | 1.14× |
| 2020-09-30 | $9.59B | $4.69B | $7.08B | $78.00M | $2.43B | $3.46B | 2.04× |
| 2020-06-30 | $8.82B | $4.41B | $6.54B | $80.00M | $2.20B | $3.44B | 2.00× |
| 2020-03-31 | $6.69B | $4.16B | $3.96B | $84.00M | $2.65B | $3.36B | 1.61× |
| 2019-12-31 | $7.32B | $4.40B | $4.34B | $88.00M | $2.89B | $3.28B | 1.66× |
| 2019-09-30 | $4.47B | $3.92B | $1.95B | $88.00M | $2.44B | $3.27B | 1.14× |
| 2019-06-30 | $4.25B | $3.95B | $1.75B | $85.00M | $2.41B | $3.20B | 1.08× |
| 2019-03-31 | $4.04B | $3.71B | $1.67B | $84.00M | $2.28B | $3.06B | 1.09× |
| 2018-12-31 | $6.03B | $4.81B | $3.62B | $83.00M | $2.33B | $2.96B | 1.25× |
| 2018-09-30 | $4.29B | $4.15B | $1.92B | $292.00M | $2.08B | $2.89B | 1.03× |
| 2018-06-30 | $4.01B | $4.05B | $1.64B | $279.00M | $2.09B | $2.74B | 0.99× |
| 2018-03-31 | $4.56B | $4.80B | $2.18B | $276.00M | $2.11B | $2.66B | 0.95× |
| 2017-12-31 | $4.99B | $3.48B | $2.54B | $251.00M | $2.20B | $2.46B | 1.43× |
| 2017-09-30 | $4.65B | $3.26B | $2.59B | $97.00M | $1.97B | $2.45B | 1.43× |
| 2017-06-30 | $5.65B | $3.55B | $3.65B | $98.00M | $1.91B | $2.28B | 1.59× |
| 2017-03-31 | $5.15B | $2.55B | $3.21B | $66.00M | $1.88B | $2.17B | 2.02× |
| 2016-12-31 | $5.35B | $3.15B | $3.32B | $68.00M | $1.97B | $2.03B | 1.70× |
| 2016-09-30 | $4.83B | $3.03B | $2.95B | $69.00M | $1.80B | $2.09B | 1.59× |
| 2016-06-30 | $5.41B | $3.60B | $3.49B | $166.00M | $1.76B | $1.99B | 1.50× |
| 2016-03-31 | $9.07B | $3.19B | $6.98B | $507.00M | $1.59B | $1.77B | 2.85× |
| 2015-12-31 | $5.74B | $3.50B | $3.38B | $700.00M | $1.66B | $1.64B | 1.64× |
| 2015-09-30 | $4.87B | $3.55B | $3.16B | $209.00M | $1.50B | $1.67B | 1.37× |
| 2015-06-30 | $5.78B | $3.72B | $3.63B | $651.00M | $1.50B | $1.62B | 1.55× |
| 2015-03-31 | $5.78B | $3.69B | $1.67B | $2.59B | $1.52B | $1.58B | 1.57× |
| 2014-12-31 | $6.57B | $4.46B | $1.79B | $3.21B | $1.57B | $1.59B | 1.47× |
| 2014-09-30 | $6.21B | $4.21B | $1.36B | $3.32B | $1.53B | $1.67B | 1.47× |
| 2014-06-30 | $6.25B | $3.71B | $1.32B | $3.43B | $1.50B | $1.59B | 1.68× |
| 2014-03-31 | $5.48B | $3.56B | $1.38B | $2.67B | $1.43B | $1.50B | 1.54× |
| 2013-12-31 | $5.50B | $2.66B | $1.34B | $2.64B | $1.52B | $1.42B | 2.07× |
| 2013-09-30 | $6.51B | $2.32B | $1.11B | $4.03B | $1.37B | $1.40B | 2.80× |
| 2013-06-30 | $6.07B | $1.97B | $971.00M | $3.68B | $1.41B | $1.34B | 3.08× |
| 2013-03-31 | $5.89B | $1.81B | $1.91B | $2.57B | $1.41B | $1.32B | 3.26× |
| 2012-12-31 | $5.71B | $1.88B | $1.40B | $2.89B | $1.43B | $1.26B | 3.05× |
| 2012-09-30 | $5.22B | $1.58B | $1.42B | $2.44B | $1.36B | $1.31B | 3.31× |
| 2012-06-30 | $4.83B | $1.49B | $1.39B | $2.07B | $1.37B | $1.29B | 3.24× |
| 2012-03-31 | $4.77B | $1.55B | $690.00M | $2.61B | $1.47B | $1.32B | 3.08× |
| 2011-12-31 | $4.83B | $1.83B | $905.00M | $2.51B | $1.42B | $1.28B | 2.64× |
| 2011-09-30 | $4.53B | $1.56B | $810.00M | $2.40B | $1.32B | $1.30B | 2.90× |
| 2011-06-30 | $4.02B | $1.60B | $497.10M | $2.18B | $1.35B | $1.28B | 2.51× |
| 2011-03-31 | $4.20B | $1.59B | $735.10M | $2.15B | $1.31B | $1.22B | 2.64× |
| 2010-12-31 | $5.63B | $1.60B | $1.76B | $2.62B | $1.25B | $1.06B | 3.51× |
| 2010-09-30 | $5.67B | $1.41B | $925.60M | $3.59B | $1.16B | $1.04B | 4.03× |
| 2010-06-30 | $5.14B | $1.30B | $785.20M | $3.24B | $1.11B | $968.20M | 3.97× |
| 2010-03-31 | $5.06B | $1.40B | $1.20B | $2.74B | $1.12B | $961.00M | 3.60× |
| 2009-12-31 | $4.10B | $1.44B | $658.70M | $2.30B | $1.15B | $943.00M | 2.85× |
| 2009-09-30 | $4.04B | $1.20B | $960.30M | $1.97B | $1.11B | $977.30M | 3.37× |
| 2009-06-30 | $3.53B | $1.08B | $666.30M | $1.76B | $1.10B | $991.70M | 3.28× |
| 2008-12-31 | $3.33B | $1.46B | $701.10M | $1.49B | $1.13B | $952.70M | 2.27× |
| 2007-12-31 | (m) | (m) | $290.50M | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $416.60M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |